JP2017538672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538672A5 JP2017538672A5 JP2017522532A JP2017522532A JP2017538672A5 JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5 JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cmv
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 11
- 241001465754 Metazoa Species 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 101710132601 Capsid protein Proteins 0.000 claims 4
- 101710094648 Coat protein Proteins 0.000 claims 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 4
- 101710125418 Major capsid protein Proteins 0.000 claims 4
- 101710141454 Nucleoprotein Proteins 0.000 claims 4
- 101710083689 Probable capsid protein Proteins 0.000 claims 4
- 210000004897 n-terminal region Anatomy 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 239000013566 allergen Substances 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 241000223960 Plasmodium falciparum Species 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 102100023688 Eotaxin Human genes 0.000 claims 1
- 101710139422 Eotaxin Proteins 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 1
- 101900330356 Influenza A virus Matrix protein 2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 229940118376 tetanus toxin Drugs 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14189897 | 2014-10-22 | ||
| EP14189897.3 | 2014-10-22 | ||
| EP15184192 | 2015-09-08 | ||
| EP15184192.1 | 2015-09-08 | ||
| PCT/EP2015/074269 WO2016062720A1 (en) | 2014-10-22 | 2015-10-20 | Modified virus-like particles of cmv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538672A JP2017538672A (ja) | 2017-12-28 |
| JP2017538672A5 true JP2017538672A5 (enExample) | 2018-11-22 |
| JP6942313B2 JP6942313B2 (ja) | 2021-09-29 |
Family
ID=54337283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522532A Active JP6942313B2 (ja) | 2014-10-22 | 2015-10-20 | Ｃｍｖ由来改変ウイルス様粒子 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10532107B2 (enExample) |
| EP (1) | EP3209326A1 (enExample) |
| JP (1) | JP6942313B2 (enExample) |
| KR (2) | KR20250034187A (enExample) |
| CN (2) | CN114685626B (enExample) |
| AU (1) | AU2015335027B2 (enExample) |
| CA (1) | CA2963709A1 (enExample) |
| CL (1) | CL2017000987A1 (enExample) |
| CO (1) | CO2017004119A2 (enExample) |
| IL (1) | IL251532B (enExample) |
| MA (1) | MA40824A (enExample) |
| MX (1) | MX387985B (enExample) |
| MY (1) | MY187462A (enExample) |
| NZ (1) | NZ731205A (enExample) |
| PE (1) | PE20171133A1 (enExample) |
| PH (1) | PH12017500727A1 (enExample) |
| RU (1) | RU2706970C2 (enExample) |
| SG (2) | SG11201703083QA (enExample) |
| TN (1) | TN2017000133A1 (enExample) |
| WO (1) | WO2016062720A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| WO2017179025A1 (en) | 2016-04-15 | 2017-10-19 | Alk-Abelló A/S | Epitope polypeptides of ragweed pollen allergens |
| EA201892003A1 (ru) * | 2016-04-27 | 2019-05-31 | Бенчмарк Энимал Хэлс Лтд. | Лечение атопического дерматита собак |
| US10898569B2 (en) | 2016-04-27 | 2021-01-26 | Allergy Therapeutics (Uk) Limited | Treatment of peanut allergy |
| EP3592378A1 (en) * | 2017-03-07 | 2020-01-15 | Universität Zürich | Treatment of pruritus in horses |
| SG11202005526WA (en) * | 2017-12-11 | 2020-07-29 | Ubi Ip Holdings | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis |
| AU2019236328B2 (en) * | 2018-03-16 | 2025-10-09 | Zoetis Services Llc | Peptide vaccines against Interleukin-31 |
| CA3095983A1 (en) | 2018-04-10 | 2019-10-17 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
| AU2019278596A1 (en) | 2018-05-28 | 2020-12-24 | Evax Ag | Treatment of urticaria |
| SG11202104486VA (en) | 2018-12-20 | 2021-05-28 | Saiba AG | Virus-like particles of cmv modified by fusion |
| US20220073582A1 (en) * | 2018-12-31 | 2022-03-10 | United Neuroscience Limited | Peptide immunogens targeting calcitonin gene-related peptide (cgrp) and formulations thereof for prevention and treatment of migraine |
| WO2021083766A1 (en) | 2019-10-29 | 2021-05-06 | Evax Ag | Treatment of pruritus in horses |
| WO2021108202A1 (en) * | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Modified viral therapeutics and uses thereof |
| WO2021260131A1 (en) | 2020-06-25 | 2021-12-30 | Saiba AG | Virus-like particles of cmv modified by fusion |
| IL302741A (en) * | 2020-11-11 | 2023-07-01 | European Molecular Biology Laboratory | Viral particles adapted for gene therapy |
| CN116981691A (zh) * | 2020-11-23 | 2023-10-31 | 斯克奥特比奥股份有限公司 | 抗原结合分子及其用途 |
| CN117534736A (zh) * | 2020-12-15 | 2024-02-09 | 深圳赫兹生命科学技术有限公司 | 一种用于生产vlp重组疫苗的cmv病毒样颗粒及其制备方法 |
| US20250114444A1 (en) | 2022-01-19 | 2025-04-10 | Universität Bern | Compositions of virus-like particles and microcrystalline tyrosine |
| CN114437211B (zh) * | 2022-01-26 | 2024-03-12 | 南京麦西崴克生物科技有限公司 | 基于猫过敏原Fel d1的卵黄抗体的制备方法 |
| US20250186596A1 (en) | 2022-02-28 | 2025-06-12 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
| CN119136838A (zh) | 2022-02-28 | 2024-12-13 | 特瑞德姆生物科技有限责任两合公司 | 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物 |
| AU2023332017A1 (en) | 2022-08-30 | 2025-03-06 | Saiba Animal Health Ag | Veterinary compositions of modified virus-like particles of cmv and ngf antigens |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
| GB202400747D0 (en) * | 2024-01-19 | 2024-03-06 | Univ Dundee | IL31-VLP and medical uses thereof |
| TW202536171A (zh) | 2024-03-04 | 2025-09-16 | 德商百靈佳殷格翰獸藥股份有限公司 | 用於治療ｎｇｆ相關病症之主動疫苗接種 |
| US20250281585A1 (en) | 2024-03-06 | 2025-09-11 | Elanco Us Inc. | Veterinary compositions of modified virus-like particles of cmv and il-1 beta mutein antigens |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| JP2002518033A (ja) * | 1998-06-20 | 2002-06-25 | ユナイティド バイオメディカル インコーポレイティド | 農場動物の成長促進のための合成ソマトスタチン免疫原 |
| AU2001252458A1 (en) * | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
| AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| JP4533626B2 (ja) * | 2001-11-07 | 2010-09-01 | サイトス バイオテクノロジー アーゲー | アレルギー性好酸球性疾患を治療するための抗原アレイ |
| PL369863A1 (en) | 2001-11-07 | 2005-05-02 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| EP1545625B1 (en) | 2002-06-07 | 2011-08-24 | Kentucky Bioprocessing, LLC | Flexible vaccine assembly and vaccine delivery platform |
| GB0228715D0 (en) * | 2002-12-09 | 2003-01-15 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2005091753A2 (en) * | 2004-03-25 | 2005-10-06 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
| EP1791870A1 (en) * | 2004-09-21 | 2007-06-06 | Cytos Biotechnology AG | Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| JP2008530137A (ja) * | 2005-02-14 | 2008-08-07 | ザイモジェネティクス，インコーポレイティド | 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法 |
| CN101141979B (zh) * | 2005-03-18 | 2013-05-08 | 赛托斯生物技术公司 | 猫变应原融合蛋白及其用途 |
| US20070184068A1 (en) * | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| WO2011150264A2 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Synthetic nanocarrier combination vaccines |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| HUP1100470A2 (en) * | 2011-08-30 | 2013-03-28 | Mezoegazdasagi Biotechnologiai Kutatokoezpont | Nanoparticle-based veterinary vaccine |
| CN102943087A (zh) * | 2012-11-26 | 2013-02-27 | 中国农业科学院上海兽医研究所 | 兔出血症病毒新型亚单位疫苗及其制备方法 |
| WO2015065322A1 (en) | 2013-10-28 | 2015-05-07 | Hitachi, Ltd. | De-duplication and host based qos in tiered storage |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| EP3347040A1 (en) * | 2015-09-08 | 2018-07-18 | Universität Zürich | Treatment of insect bite hypersensitivity |
| EP3347046B1 (en) * | 2015-09-08 | 2022-10-19 | Universität Zürich | Compositions against cat allergy |
-
2015
- 2015-10-19 MA MA040824A patent/MA40824A/fr unknown
- 2015-10-20 PE PE2017000737A patent/PE20171133A1/es unknown
- 2015-10-20 JP JP2017522532A patent/JP6942313B2/ja active Active
- 2015-10-20 MY MYPI2017701368A patent/MY187462A/en unknown
- 2015-10-20 KR KR1020257006196A patent/KR20250034187A/ko active Pending
- 2015-10-20 NZ NZ731205A patent/NZ731205A/en unknown
- 2015-10-20 MX MX2017005242A patent/MX387985B/es unknown
- 2015-10-20 KR KR1020177013820A patent/KR102775741B1/ko active Active
- 2015-10-20 AU AU2015335027A patent/AU2015335027B2/en active Active
- 2015-10-20 SG SG11201703083QA patent/SG11201703083QA/en unknown
- 2015-10-20 CA CA2963709A patent/CA2963709A1/en active Pending
- 2015-10-20 SG SG10201903538YA patent/SG10201903538YA/en unknown
- 2015-10-20 WO PCT/EP2015/074269 patent/WO2016062720A1/en not_active Ceased
- 2015-10-20 RU RU2017111266A patent/RU2706970C2/ru active
- 2015-10-20 CN CN202210351341.8A patent/CN114685626B/zh active Active
- 2015-10-20 TN TN2017000133A patent/TN2017000133A1/en unknown
- 2015-10-20 US US15/520,676 patent/US10532107B2/en active Active
- 2015-10-20 CN CN201580064884.XA patent/CN108064276B/zh active Active
- 2015-10-20 EP EP15781949.1A patent/EP3209326A1/en active Pending
-
2017
- 2017-04-03 IL IL251532A patent/IL251532B/en active IP Right Grant
- 2017-04-20 PH PH12017500727A patent/PH12017500727A1/en unknown
- 2017-04-20 CL CL2017000987A patent/CL2017000987A1/es unknown
- 2017-04-27 CO CONC2017/0004119A patent/CO2017004119A2/es unknown
-
2019
- 2019-11-26 US US16/696,161 patent/US11324836B2/en active Active
-
2022
- 2022-04-06 US US17/714,307 patent/US20220305131A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538672A5 (enExample) | ||
| RU2017111266A (ru) | Модифицированные вирусоподобные частицы вируса мозаики огурца | |
| Balke et al. | Recent advances in the use of plant virus-like particles as vaccines | |
| RU2486206C2 (ru) | Гипоаллергенный слитый белок, молекула нуклеиновой кислоты, кодирующая его, вектор экспрессии, клетка-хозяин, вакцинная композиция и его применение | |
| JP2014530010A5 (enExample) | ||
| Deng et al. | Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge | |
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| JP2015501840A5 (enExample) | ||
| JP2010516290A5 (enExample) | ||
| Shim et al. | Sublingual delivery of vaccines for the induction of mucosal immunity | |
| JP2011250797A5 (enExample) | ||
| JP2012501959A5 (enExample) | ||
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| JP2019506175A5 (enExample) | ||
| Chai et al. | DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss | |
| JP2024504566A (ja) | 核酸ワクチン | |
| TW202202169A (zh) | 預防嚴重急性呼吸症候群冠狀病毒第二型（ｓａｒｓ－ｃｏｖ－２）感染的生物可降解奈米複合物疫苗及方法 | |
| JP2016511747A5 (enExample) | ||
| JP2010506926A5 (enExample) | ||
| Nagpal et al. | Current clinical status of new COVID-19 vaccines and immunotherapy | |
| Mansoor et al. | Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice | |
| JP2015529677A5 (enExample) | ||
| Nie et al. | Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice | |
| Ramirez et al. | Co‐Delivery of Multiple Toll‐Like Receptor Agonists and Avian Influenza Hemagglutinin on Protein Nanoparticles Enhances Vaccine Immunogenicity and Efficacy | |
| Ding et al. | A Universal Influenza Nanovaccine for “Mixing Vessel” Hosts Confers Potential Ability to Block Cross‐Species Transmission |